BBIO vs. TMO: BridgeBio Pharma vs. Thermo Fisher Scientific Stock Comparison

Company Profile

BridgeBio Pharma (BBIO) and Thermo Fisher Scientific (TMO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BBIO is classified in Biotechnology while TMO is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Thermo Fisher Scientific (TMO) earns 13.38% on shareholders’ equity, ranked against its industry; BridgeBio Pharma (BBIO) has no ROE this period.

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Thermo Fisher Scientific (TMO) reports 14.94%, ranking against industry peers normally.

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Thermo Fisher Scientific (TMO) reports 20.19%, ranking against industry peers normally.

Profitability Metrics

Growth

BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while Thermo Fisher Scientific (TMO) at 3.91% is closer to the peer norm — faster top-line expansion for BBIO.

Only one side can be read here: Thermo Fisher Scientific (TMO) reports EPS growth of 7.32%, ranked against its industry; BridgeBio Pharma (BBIO) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both BridgeBio Pharma (BBIO) at 2.09 and Thermo Fisher Scientific (TMO) at 1.81 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Only one side’s leverage can be read here: Thermo Fisher Scientific (TMO) carries debt-to-equity ratio of 0.75 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.

Financial Strength Metrics

Dividends

BridgeBio Pharma (BBIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a yield of 0.27%, ranking against industry peers normally.

BridgeBio Pharma (BBIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Thermo Fisher Scientific (TMO) reports a payout of 9.70%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Thermo Fisher Scientific (TMO) trades at 36.64 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.

On P/S ratio, both BridgeBio Pharma (BBIO) at 15.31 and Thermo Fisher Scientific (TMO) at 5.44 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Thermo Fisher Scientific (TMO) reports 4.70, ranking against industry peers normally.

Valuation Metrics